Vivos Therapeutics

Vivos Announces Strong Momentum and Revenue Growth Prospects in 2024

Vivos Therapeutics, Inc. (the “company” or “Vivos”) (NASDAQ: VVOS), a leading medical device and...

Vivos Therapeutics Presents: “Empowering Women to Champion Airway”

Vivos Therapeutics is excited to announce “Empowering Women to Champion Airway,” a pioneering event...

Vivos Achieves Landmark FDA Clearance for Sleep Apnea Solution

Vivos Therapeutics, Inc. (NASDAQ: VVOS), a prominent medical device and technology company specializing in...

Vivos Therapeutics Schedules Release of Third Quarter 2023 Financial Results and Conference Call

Vivos Therapeutics, Inc. (“Vivos” or the “company”) (NASDAQ: VVOS), a medical technology company focused...

Vivos Therapeutics and Candid Announce Strategic Collaboration to Deliver A Comprehensive Sleep Apnea and Orthodontic Treatment Solution

Vivos Therapeutics, Inc., a medical technology company focused on developing and commercializing innovative diagnostic and...

Vivos Therapeutics Announces Formation of New Medical Consortium to Advance the Company’s Technology for Obstructive Sleep Apnea

Drs. Clete Kushida of Stanford and Cecilia Wu of University of Alberta to lead...

FDA Grants 510(k) Market Clearance to Vivos Therapeutics’ mmRNA Oral Appliance for Treating Mild to Moderate Sleep Apnea

Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ: VVOS), a medical technology company focused...

Vivos Therapeutics Opens State of the Art International Training Center In Denver

Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ: VVOS), a medical technology company focused...

Vivos Therapeutics Establishes Clinical Advisory Board

Vivos Therapeutics has established a clinical advisory board to drive adoption and growth of...